Regeneron EVP Joseph LaRosa Exercises Options, Sells Shares

What Happened Joseph J. LaRosa, EVP, General Counsel and Secretary of Regeneron Pharmaceuticals (REGN), exercised stock options on 2026-08-19 to acquire 12,282 shares at an exercise price of $381.92 per share (total value reported $4,690,741). To cover tax withholding, 9,019 of those shares were surrendered/disposed at a market price of $830.15 per share (value ~$7,487,123). The underlying derivative position was reported as converted/terminated in the filing (derivative disposed at $0).

Key Details

• Transaction date: 2026-08-19; Form 4 filed 2026-08-21 (within the two-business-day SEC window).
• Option exercise: 12,282 shares @ $381.92 (acquired) — reported value $4,690,741.
• Tax withholding/disposition: 9,019 shares @ $830.15 (disposed) — reported value $7,487,123.
• Derivative (option) reported disposed at $0 (reflects conversion of the option into shares).
• Shares owned after the transaction: not specified in the filing.
• Footnote: F1 — the option award vests in four equal annual installments starting one year after grant.

Context This was an option exercise with net-share withholding to satisfy tax obligations (common practice); effectively LaRosa acquired 12,282 shares and surrendered 9,019 to cover taxes, leaving a net increase of 3,263 shares retained (12,282 - 9,019 = 3,263). Such transactions are routine for vested option awards and do not by themselves indicate a change in insider sentiment.